NYTimes explores cellular rejuvenation biotech frontiers
Posted by student748 in Longevity & Anti-Aging - 1 points, 0 comments.
Came across this NYTimes piece on cellular rejuvenation and Altos Labs, the article frames it as one of the newest promising developments in longevity research since the 1993 UCSF study that doubled lifespan in model organisms. What stuck with me is how they’re talking about reversing aging rather than just slowing it, which feels like a real shift in the conversation. Having followed the peptide and compound space for a while now, stuff like NAD+, rapamycin, GHK-Cu all feel like we’re in the "slowing" phase, but the idea of actual rejuvenation is a different beast entirely. The piece left me skeptical but curious, a lot of the claims feel early-stage, and i’m curious how much of this will translate to things we can actually use versus staying in the lab pipeline.
Question is: does this kind of cellular rejuvenation research ever make it down to the level of compounds we’re actually cycling, or does it stay in the academic/biotech early phase where we won’t see practical applications for years?
Community discussion - research and educational context only. Not medical advice.